Listen "95. Modality convergence in advanced therapies"
Episode Synopsis
Join us in this lite bite episode as Dr. Aravind Asokan, Duke University, explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment.
This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).
Show notes
Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022
This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).
Show notes
Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022
More episodes of the podcast Discovery Matters
112. Best of 2025
21/12/2025
111. Brain tumors
17/12/2025
110. Dr Spendlove
08/12/2025
109. The art of delivery: mRNA meets LNP
19/11/2025
108. Metastatic breast cancer
09/10/2025
106. Zoonotic diseases
27/06/2025
105. What is pain?
28/05/2025
104. Vaccines: Inverse v traditional
30/04/2025
103. How space impacts the body
25/04/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.